Full Breakdown
Parabilis Medicines Raises Record $745 Million in Upsized IPO, Setting New Biotech Benchmark
6/10/2026, 11:22:02 PM
Record-Breaking Upsized IPO Sets New Biotech Benchmark
Parabilis priced 33.5 million shares at $20, raising $670 million. A Regeneron private placement added $75 million, for a total of $745 million. Shares debuted on Nasdaq under PBLS, with valuations reported at $2.4 billion (Reuters) and $4 billion (Bloomberg). Demand was about ten-fold the shares offered.
Background and Market Context
The 2026 biotech IPO market’s median raise is $300 million, double 2025’s. Parabilis, founded in 2015 as Fog Pharma by Harvard professor Greg Verdine, rebranded after raising over $800 million. It targets “undruggable” proteins with its Helicon platform.
Leadership, Partnerships, and Offering Summary
Chief Executive Mathai Mammen, a former Johnson & Johnson research executive, leads Parabilis; co-founder Greg Verdine is a biotech entrepreneur. Regeneron’s deal includes a $50 million upfront payment, $2.2 billion in milestones, and $75 million private-placement. Underwriters—Leerink, Bank of America, Evercore, Guggenheim, LifeSci Capital—have a 30-day option for 5 million extra shares. Parabilis reported a 2025 net loss of $145.9 million and cash of $27.7 million.
Use of Proceeds and Clinical Pipeline
Parabilis allocated $150 million to a Phase 3 desmoid-tumor trial of zolucatetide, $120 million for other indications, and $190 million for pipeline programs. Zolucatetide targets the Wnt/?-catenin pathway, has dosed >150 patients, and achieved 100 % tumor reduction with a 74 % objective response in desmoid cases. Early studies also explore familial adenomatous polyposis, hepatocellular carcinoma, and prostate cancer. The Phase 3 trial is slated for early 2027.
Implications for Biotech Funding and Undruggable Targets
The $745 million raise surpasses Kailera Therapeutics’ $625 million record and signals strong investor confidence in peptide platforms. The capital could accelerate therapies for proteins previously inaccessible to conventional drugs.
Official Statements & Responses
Parabilis said the funds will speed development of medicines for undruggable cancers. Regeneron called the partnership external validation. Underwriters highlighted the ten-fold oversubscription as market enthusiasm.
Conflicting Reports & Gaps
Sources differ on post-IPO valuation ($2.4 billion vs $4 billion) and total proceeds ($745 million vs $670 million). Long-term efficacy data for zolucatetide remain unavailable.
Verbatim Quotes
- “Many cancers don’t have adequate treatments because the proteins that are causing that cancer are undruggable,” — Mathai Mammen, CEO, Parabilis Medicines
- “Our whole company’s purpose is to introduce a form of peptides as a mechanism to go forward and drug these proteins that cause cancer.” — Mathai Mammen, CEO, Parabilis Medicines
- “The upsize is another strong signal that the biotech IPO pipeline is much healthier than it was last year.” — Lukas Muehlbauer, IPOX Research Associate
- “Parabilis stands out by bringing a lot of credibility to the table with the Regeneron partnership, externally validating the company’s technology,” — Lukas Muehlbauer, IPOX Research Associate
What’s Next
Parabilis will start the Phase 3 desmoid trial in early 2027, pursue additional oncology indications, and may receive Regeneron milestone payments. Market watchers will track post-IPO share performance and any follow-on offerings.
